INTRODUCTION
Shy et al. [1] originally reported a form of congenital myopathy characterized by the unique cytoplasmic aggregates, which looked like coils of thread or rods, in muscle cells. The aggregate was called as nemaline body after 'nema' meaning thread in Greek, and the disease was named as nemaline myopathy. Currently, nemaline myopathy is regarded as a heterogeneous disease entity. Most of the cases show child-onset and usually chronic progressive course with autosomal recessive or dominant inheritance pattern, and now at least 11 causative genes are identified: TPM3, NEB, ACTA1, TPM2, TNNT1, KBTBD13, CFN2, KLHL40, KLHL41, LMOD3, and MYPN [2] . Meanwhile, adult-onset form is also occasionally seen. Some of such patients have actually congenital nemaline myopathy, the symptom of which develops insidiously and manifests obviously in the adulthood. Other patients show literally adult-onset and subacute progression without any evidence of inheritance. This form is called sporadic late-onset nemaline myopathy (SLONM), which was first described by Engel [3] . However, yet, SLONM is multifactorial. SLONM with HIV infection and that with neither MGUS or HIV appear to be heterogeneous, although SLONM with HIV infection is usually responsive to corticosteroid, intravenous immunoglobulin (IVIg), and plasmapheresis [24, 25, 27, 30] . On the other hand, SLONM with MGUS (SLONM-MGUS) patients show a particular phenotype: severe weakness and atrophy in axial, limb-girdle, and occasionally distal muscles, dysphagia, and respiratory insufficiency, which are often refractory to immunotherapy [4] [5] [6] [7] 8 ]. Of note, respiratory involvement is lethal, and the majority of the patients died within 1-5 years from the onset [8 && ]. Because of this poor prognosis, our group has shown that autologous stem-cell transplantation (SCT) following high-dose melphalan (HDM-SCT) can lead to dramatical improvement in the SLONM-MGUS patients [10,11,16 && ]. Subsequently, the efficacy of HDM-SCT or chemotherapy to the plasma cell dyscrasia has been demonstrated by other groups as well [13,15,17,18 & ,19] . Hence, today, regardless of rarity of the disease, the significance of early recognition of SLONM-MGUS is increasing as the disease is lethal but now can be considered treatable. This review gives an overview of clinical and pathological features, treatments, and recent advances in SLONM-MGUS with some discussion of the cause. A recent series of case reports have suggested a possibility of cardiac muscle involvement in SLONM-MGUS [19, 20, 22 & ]. In the report of Belhomme et al. [22 & ], one SLONM-MGUS patient was admitted to the ICU due to acute heart failure after 2 years from the onset of muscle weakness at the age of 55 years. The left ventricular (LV) ejection fraction (LVEF) was reduced to 30%, but it recovered to 60% after chemotherapy of bortezomib, cyclophosphamide, and dexamethasone, together with selective beta-blockers. In another report, a 37-yearold patient was pointed out to have LV systolic dysfunction due to diffuse hypokinesia within 2 years after the onset of muscle weakness [20] . Subsequently, severe congestive heart failure with 20% of LVEF appeared, and three cardiac arrests due to ventricular tachycardia and fibrillation occurred, requiring intensive care and an implantable cardioverter defibrillator. Although response to antiplasma cell dyscrasia therapy is not mentioned, the report has described that his heart condition was controlled by ivabradine, a sinus node I f channel inhibitor, with the rehabilitation program. In the other article, an asymptomatic LV systolic dysfunction with a moderate reduction of LVEF to 42% was detected in a 44-year-old patient 5 years after the onset of muscle weakness, although response to the HDM-SCT is not mentioned [19] . These three cases showing cardiac abnormality developed 2-5 years after the onset of SLONM-MGUS may imply the presence of cardiomyopathy as an extramuscular manifestation. The case with improvement after antiplasma cell dyscrasia therapy is especially suggestive. However, only anecdotal evidence from a limited number of patients is KEY POINTS SLONM-MGUS shows subacute progressive muscle weakness with severe respiratory insufficiency.
CLINICAL FEATURES
Head drop, MGUS, and nemaline body are typical signs of SLONM-MGUS.
Heart failure possibly appears as an extramuscular involvement.
Antiplasma cell dyscrasia therapy, including autologous stem-cell transplantation following high-dose melphalan, is effective.
available at present. Also, there has been no pathological evidence, such as nemaline body in cardiac muscle cells, yet. Further investigation is necessary to solidly demonstrate cardiac muscle involvement in SLONM-MGUS.
As a concurrent autoimmune disorder, vitiligo that developed 2-year prior to the onset was reported in one patient, although the actual association remains unknown [14] . The patient showed significant improvement in muscle strength by monthly IVIg, although the response of immunotherapy toward the skin lesions was not mentioned.
Serum creatine kinase levels are within, or occasionally lower than, normal range in almost all patients. About MGUS, both types of free light chain predominance (k and l) are described (17 : 12. Two different M proteins, IgG-k and -l, were simultaneously present in one patient (biclonal gammopathy) [12] . Another patient's data was not available). Correlation of the predominant light chain type and serum M protein levels with clinical course and severity is not well known. However, the reincrease of the serum M protein levels after HDM-SCT appears to be associated with the relapse [16 && ]. One patient was described as having multiple myeloma, not MGUS, as her bone marrow aspiration showed clonal plasma cells occupied 20% of the cells [18 & ]. Screening for monoclonal immunoglobulin had been performed conventionally by means of protein electrophoresis and immunofixation. However, in the early 2000s, the serum free light chain (FLC) assay was developed [32, 33] . This technology is based on immunonephelometry using specific antibodies that react with the epitopes which are hidden when bound to a heavy chain but exposed when not associated with it [32, 33] . Some studies demonstrated that serum FLC assay in combination with serum protein electrophoresis and immunofixation could detect light chains more sensitively than the respective assay alone. Therefore, currently, the combination of the assays is recommended for screening of monoclonal gammopathy [33, 34] . When a patient is suspected to have SLONM, measurement with the combination of the assays may lead to avoid overlooking MGUS.
In muscle magnetic resonance images, patchy high intensity on T2-weighted images or short-tau inversion recovery images, which can reflect edematous change and is often observed in inflammatory myopathies, was reported, although only few reports described the images precisely [14, 21] .
Electromyography shows myopathic changes with abnormal spontaneous activity at rest in almost all cases when the results of the test were described. This pattern is observed commonly in inflammatory myopathies, albeit not disease-specific [35] .
MUSCLE PATHOLOGY
The main pathologic feature is nemaline body in myofibers (Fig. 1a) . The size of nemaline body is ]. Observation of trichromatically stained frozen sections with higher magnification is recommended. Nemaline bodies are positively stained on immunohistochemistry for Z-band proteins, such as alpha-actinin and myotilin, because nemaline bodies are derived from degenerated Z bands. On electron microscopy, nemaline bodies are morphologically confirmed by the high electron density similar to Z bands and the presence of internal lattice-like structure (Fig. 1b and c) . The ultrastructural observation contributes to distinguish from other cytoplasmic aggregates, such as cytoplasmic body and spheroid body. Intranuclear rods, which are known to be associated with severe infantile form of nemaline myopathy with ACTA1 mutation and relatively mild form with MYPN mutation, have been rarely reported [2,4,8 && ,36]. It should be noted that nemaline body per se is not specific, although its presence is a mandatory finding of nemaline myopathies. Nemaline body can be observed also in idiopathic inflammatory myopathies, alcoholic myopathy, advanced stage of muscular dystrophies, hypothyroidism, cancer invasion, and chronic neuropathy like spinal muscular atrophy [37] [38] [39] [40] [41] [42] . Empirically, a small number of fibers with nemaline bodies can be seen physiologically if the muscle is biopsied near tendon.
In congenital nemaline myopathy, bimodal distribution of fiber size, type 1 fiber predominance and atrophy, and type 2B fiber deficiency are observed. Moreover in SLONM-MGUS, type 1 fiber predominance and/or atrophy was reported in some cases, requiring attention in terms of differential diagnosis from adult-onset congenital nemaline myopathy [5] [6] [7] 8 && , 20, 21] . Although there is limited data on type 2B fiber deficiency, lack of type 2B fiber deficiency may be a pathologic differential point to distinguish both conditions [21] .
Necrotic or regenerating fibers are not seen, or rare if present, unlike muscular dystrophy and immune-mediated necrotizing myopathy. There is no significant endomysial lymphocyte infiltration as seen in polymyositis and inclusion body myositis. Expression of major histocompatibility complex class I is not observed, or detected only on sarcolemma, immunohistochemically. Chahin et al. [8 && ] mentioned that, in their experience, the biopsy findings of SLONM-MGUS were similar to HIVassociated nemaline myopathy.
Immunoreactivity for light chains on muscle tissues, mainly sarcolemma, was reported in four patients, whereas amyloid deposition was not observed [6, 7, 15, 16 && ] Based on the facts, Doppler et al. [15] inferred that SLONM-MGUS was a continuum of light-chain deposition disease (LCDD). LCDD is a rare disease characterized by deposition of monoclonal immunoglobulin light chains (commonly k type) on multiple organs (mainly kidney, liver, and heart) [43] [44] [45] [46] . The deposits are not stained with Congo-red stain and do not exhibit a fibrillar structure like amyloid but a fine granular appearance on electron microscopy [47, 48] . Their thought is consistent with the fact that light chain deposition was observed on skeletal muscles. However, the difference of affected organs/tissues between LCDD and SLONM-MGUS will have to be considered; LCDD is a multiple organ disease, but, in contrast, SLONM-MGUS affects exclusively muscles (skeletal and possibly cardiac). This selectivity may rather imply the implication of autoimmunity in the pathogenesis.
TREATMENT
During the decade, our group has shown the efficacy of HDM-SCT in SLONM-MGUS (Fig. 2) [10, 11, 16 && ]. HDM-SCT has been established as the treatment for plasma cell dyscrasia, including amyloid light chain amyloidosis and POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy/edema, M protein, skin abnormalities; Crow-Fukase syndrome). Considering the similarity to SLONM-MGUS, and its severity and rapid progression, HDM-SCT was tried [10, 11] . Since the initial reports in 2008, there have been reports of 11 patients receiving HDM-SCT from several different groups [10,11,13,15,16 && ,17,19] . Favorable response is observed in 10 out of the 11 patients. Long-standing improvement in muscle strength were observed in most of the patients, although second HDM-SCT and additional antiplasma cell chemotherapy (lenalidomide, bortezomib, cyclophosphamide, and dexamethasone) were added in five patients [15,16 && ]. The increase of the serum M protein levels preceded clinical deterioration in the two patients who required second HDM-SCT [16 && ]. Monitoring of M protein levels may be helpful for follow-up of patients. Disappearance of nemaline body was confirmed when muscle biopsy was performed after the treatment [10, 11] . Age at onset of muscle weakness, severity of muscle weakness before HDM-SCT, the level and type of M protein, and results of bone marrow aspiration before the transplantation did not correlate with the clinical response [16 && ]. One patient died of Salmonella typhi septicemia 5 months after the treatment, despite significant improvement in muscle strength [19] . The only one patient who showed neither a clinical nor hematologic response to the HDM-SCT received additional chemotherapy, but later she died [16 && ]. The factors of unfavorable outcome in the patient were considered as a long disease course before HDM-SCT (11 years) and a poor hematologic response to the treatments.
The mortality rates within 100 days after HDM-SCT were reported to be 1.9% in multiple myeloma and 13-24% in amyloid light chain amyloidosis [49, 50] . The mortality might be influenced by involved organs. A large population study, enrolling 701 consecutive patients with amyloid light chain amyloidosis, revealed that the survival of the participants treated by HDM-SCT was adversely affected by the presence of cardiac involvement [50] . The same study also reported that there was no difference in the survival of the participants aged over 65 years compared with younger participants (eligible patients up to age 80 years were treated in the study) [50] , although a prior study of another group had suggested that patients 65 years of age or older should not be considered for the treatment [51] . In SLONM-MGUS, as described early, cardiac muscle involvement is possible, and elderly patients can also be encountered [8 && ,19,20,22 & ]. In such cases, indication of HDM-SCT should be considered more carefully. Recently, some chemotherapies without SCT for multiple myeloma have been developed [52] . In patients with risk, such therapies might be an option. Belhomme et al. [22 & ] reported that a patient with cardiac failure possibly related to MGUS received a chemotherapy without SCT (four cycle of the bortezomib-cyclophosphamide-dexamethasone) and showed a significant improvement in motricity and cardiac function. Montagnese et al. [18 & ] also described a patient with one cycle of lenalidomide-dexamethasone therapy showed a significant improvement. Furthermore, in the report of Doppler et al. [15] , bortezomib with dexamethasone AE cyclophosphamide was effective toward relapse after HDM-SCT. These cases suggest a possible efficacy of antiplasma cell dyscrasia therapy without SCT in SLONM-MGUS.
Immunotherapy and plasmapheresis without or before any antiplasma cell dyscrasia therapy were done in 18 patients [4] [5] [6] [7] 8 && ,11,12,14,16
The outcomes are summarized in Table 1 . Among immunotherapies, IVIg alone or in a combination with other immunotherapies seems relatively hopeful; it showed favorable responses in six out of nine patients (significant improvement in three [14, 21] , modest improvement in one [12] , and inhibition of progression in two [8 && ,21]). There is one report showing a patient whose muscle strength improved and remained stable with methylprednisolone and azathioprine [7] , but, collectively, corticosteroid alone or with immunosuppressants would not be promising [4-6,8 && ,11,12,21] . Considering the increase of serum M protein levels preceding the relapse after HDM-SCT, SLONM-MGUS may be classified as a disease associated with toxic M proteins, like POEMS syndrome [16 && ]. In POEMS syndrome, not the deposition of the monoclonal immunoglobulins in affected tissues but the antibody activity toward autoantigens, which is possibly augmented by other humoral mediators, such as vascular endothelial growth factor, is considered causative [53] . POEMS syndrome and other-related disorders show a similar response to HDM-SCT as observed in the SLONM-MGUS patients. Yet, the exact role of the M proteins in SLONM-MGUS remains unknown. Albeit lack of consistency of efficacy, the presence of patients showing favorable responses to immunotherapies including IVIg may provide indirect evidence that SLONM-MGUS has a dysimmune cause.
CONCLUSION
SLONM-MGUS is a severe, lethal disease, but today it is considered as a treatable disease. There are three typical features of SLONM-MGUS in clinical, serological, and pathological aspects: head drop, MGUS, and nemaline body. Although each of them is not a specific finding, their combination is a hallmark of the disease. Antiplasma cell dyscrasia therapy, such as HDM-SCT, is beneficial for SLONM-MGUS patients.
At present, the pathomechanic link between muscle degeneration and monoclonal gammopathy remains unclear. Further investigation is necessary and the better understanding of the pathogenesis will lead to development of more effective and safer therapy.
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